CA2161681A1 - Water soluble derivatives of camptothecin and their use as antitumor agents - Google Patents
Water soluble derivatives of camptothecin and their use as antitumor agentsInfo
- Publication number
- CA2161681A1 CA2161681A1 CA002161681A CA2161681A CA2161681A1 CA 2161681 A1 CA2161681 A1 CA 2161681A1 CA 002161681 A CA002161681 A CA 002161681A CA 2161681 A CA2161681 A CA 2161681A CA 2161681 A1 CA2161681 A1 CA 2161681A1
- Authority
- CA
- Canada
- Prior art keywords
- camptothecin
- lower alkyl
- ethylenedioxy
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention relates to water soluble, camptothecin derivatives of formula (I), wherein: n represents the integer 1 or 2; and i) R1 represents: hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower allcyl, lower alkylamino lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr wherein: t is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazol, with one or more substituents independently selected from hydroxy, methoxy, halogen, and amino; and R2 represents: diphenylmethyl or (CH2)tAr; or ii) R1 and R2 taken together with the linking nitrogen represent N-tetrahydroquinolyl or N-tetrahydroisoquinolyl; and the pharmaceutically acceptable salts and solvates thereof, their use in the treatment of tumors and methods of their preparation.
Description
w o 94/25466 PCTrUS94/04681 The present invention relates to water soluble, camptothecin derivatives substituted in the 7 positionJ their use in the treatment of tumors and methods of 5 their preparation.
BACKGROUND OFTHE INVENTION
Camptothecin, a natural, cytotoxic a~kaloid, is a topoisomerase I inhibitor and 10 potent antitumor agent. It was first isolated from the leaves and bark of the Chinese plant, Camptotheca accuminata, by Wall, et. al. (J. Am. Chem. Soc., 88 3888 (1 966)).
As depicted, camptothecin is a fused ring system, composed of a quinoline (A
15 and B), fused to a pyrrolidine ring (C), fused to an alpha-pyridone ring (D) which in turn is fused to a lactone ring (E).
CAMPTOTHECIN
~
20 It has an asymmetric carbon at the 20 position making two enantiomeric forms possible. However, the natural occurring compound is found in the "S" configura-tion as shown above.
Cytotoxic agents are often employed to control or eradicate tumors i.e., they 25 are chemotherapeutic agents. Camptothecin's cytotoxic activity is thought to be di-rectly related to camptothecin's potency as a topoisomerase inhibitor. [For detailed explanations of the topoisomerase function see A. Lehninger, Principles of Biochemisfry, 813, Worth Publishers, New York (1982); L. F. Liu, "DNA
Topoisomerases," CRC Critical Review in Biochemistry, 1-24,15 (1983) and H
30 Vosberg, ~DNA Topoisomerases: Enzymes that Control DNA Conformation,"
Current Topics in Microbiology and Immunology, 19, Springer-Verlag, Berlin 2 ~ 8 l WO 94/2~466 PCT/US94/04681 (1985).] In particular, camptothecin has been shown to be effective in the treatment of leukemia (L-1210) and certain solid tumors in laboratory animals, e.g., see Chem. Rev. 23, 385 (1973) and Cancer Treaf. Rep., 60, 1007 (1967).
Unfortunately, in the ciinic camptothecin's promise as an effective antitumor agent has not bee~ completely fulfilled. Camptothecin is essentially insoluble in physiologically compatible, aqueous media, and must be modified to make it suffi-ciently soluble for parenteral administration, a preferred mode for antitumor treat-ment. It can be made soluble by forming its sodium salt, that is, by opening thelactone with sodium hydroxide (see F.M. Muggia, et al., Cancer Chemotherapy Reports, pt. 1, 56, No.4, 515 (1972)). However, M. C. Wani, et al., J. Med. Chem., 23, 554 (1980), reported that the alpha-hydroxy lactone moiety of ring E is an abso-lute requirement for antitumor activity.
In the art there are examples of modifications and derivatives of camptothecin prepared to improve its solubility in water. Although many of these derivatives were active in vitro and in early animal studies using leukemia (L-1210) models, theywere disappointing in chronic, animal models involving implanted solid tumors.
Miyasaka, et al., U.S. Patent No. 4,399,282, discloses a group of camptothecin derivatives substituted at the 7 position with, inter alia, hydroxymethyl and alkoxymethyl. Further, Miyasaka, et. al. in U.S. patent No. 4,399,276 discloses camptothecin-7-aldehyde and certain related aldehyde derivatives such as acetals, oximes and hyrazones. More recently, Vishnuvajjala, et al., in U.S. Patent No.
4,943,579, claimed a series of water-soluble camptothecin derivatives with sub-stituents on the A ring as does Boehm, et al., European Patent Application 0 321122 A2. Other examples of derivatives of camptothecin include Miyasaka, et al., U.S. Patent No. 4,473,692 and No. 4,545,880; and W. Kingsbury, et al., J Med.
Chem., 34, 98 (1991). None of these references reported compounds with antitu-mor activity greater than that of camptothecin itself.
Wani and co-workers reported that 10, 11-methylenedioxycamptothecin is more potent than unsubstituted camptothecin (see M. C. Wani, et al., J. Med. Chem, 29, 23~8 (1986) and 30, 2317 (1987)). However, its water solubility is as poor as camptothecin which seriously limits its clinical utility.
We have now found water-soluble analogs of camptothecin with good topoi-somerase I inhibitory activity in vitro, and impressive, antitumor activity in vivo.
21 61 ~81 ~0 94125466 PCT/US94/04681 SUMMARY OF THE INVENTION
One aspect of the present invention is the water-soluble camptothecin analogs of formula (I), , ~
(~
OH
wherein:
n represents the integer 1 or 2; and i) R1 represents:
hydrogen, lower alkyl, (C3 7)cycloalkyl, (C3 7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkylamino lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr 1 5 wherein:
t is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl, with one or more substituents independently selected from hydroxy, methoxy, halogen, and amino;
and R2 represents:
diphenylmethyl or(CH2)tAr; or ii) R1 and R2 taken together with the linking nitrogen represent;
N-tetrahydroquinolyl or N-tetrahydroisoquinolyl;
and the pharmaceutically acceptable salts and solvates thereof.
Pharmaceutically acceptable salts include, but are not limited to salts with in-organic acids such hydrochloride, sulfate, phosphate, diphosphate, hydrobromide 216168~
WO 94/2~i466 PCT/US94/04681--and nitrate or salts with an organic acid such as acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, palmoate, salicylate and stearate. Other acids such as oxalic, while not in themselves phar-maceutically acceptable, may be useful as intermediates in obtaining the com-5 pounds of the invention and their pharmaceutically acceptable salts.
Another aspect of the invention is a method of inhibiting topoisomerase Type I
in mammalian cells comprising àdministering to a patient a topoisomerase inhibit-ing amount of a compound of formula (I), and a method of treating a tumor in a 10 mammal comprising administering to a mammal bearing a tumor, an effective anti-tumor amount of a compound of formula (I). A further aspect comprises pharma-ceutical formulations containing a compound of formula (I) as an active ingredient.
Methods of preparation of the compounds of formula (I) and the associated novel chemical intermediates used in the synthesis, as taught herein, are also within the 15 scope of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
Compounds As used herein the term "lower" in reference to alkyl and alkoxy means 1-6 carbons, especially 1-3 carbons, and in reference to alkenyl means 3-6 carbons (provided that the double bond is not attached to the carbon which is attached to the nitrogen). As use herein, the term ~arylU means aromatic ring substituents, e.g., 25 phenyl, napthyl, furyl, pyridyl, N-methylpyrrolyl or imidazolyl. The group "(CH2) also includes branched alkylene chains where branching is possible.
As use herein the terms "N-tetrahydroquinolyl" and "N-tetrahydroisoquinolyl"
are defined as follows:
N-tetrahydroquinolyl N-tetrahydroisoquinolyl The lactone ring, i.e., ring E, of the camptothecin moiety may be opened by 35 alkali metal or alkaline-earth metal bases, for example sodium hydroxide or calcium hydroxide, to form alkali metal or alkaline-earth metal salts of the 21 6l 68l ~WO 94/2~466 PCTIUS94/04681 corresponding open E ring form of the compounds of formula (1). Because of its better solubility in water, the open E ring form may advantageously be purified by conventional recrystallization techniques. Accordingly, said open E ring form may then be used as an intermediate to form the compounds of formula (1), for example 5 by treatment with acid, e.g., hydrochloric acid, and thereby produce a purified form of the compounds of formula (1).
As noted above, the camptothecin moiety has an asymmetric carbon atom at the 20 position making two enantiomeric forms, i.e., UR" and "S" configurations,possible. This invention includes both enantiomeric forms and any combinations of these forms. For simplicity, where no specific configuration at the 20 position is depicted in the structural formulas, it is to be understood that both enantiomeric forms and mixtures thereof are represented. Unless noted otherwise, the nomen-clature convention, ''(R,S)U, denotes a racemic (approximately equal portion) mix-ture of the R and S enantiomers while ~(R)u and "(S)" denote essential opticallypure R and S enantiomers respectively. Also included in the invention are other forms of the compound of formula (1), such as solvates, hydrates, polymorphs andthe like.
One sub group of compounds of the present invention are the compounds of formula (I) wherein:
n represents the integer 1 or 2; and j) R1 represents:
hydrogen, lower alkyl, (C3 7)cycloalkyl, (C3 7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr wherein:
t is O to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl, with one or more substituents selected from hydroxy, methoxy, halogen, and amino; or R2 represents:
diphenylmethyl or(CH2)tAr; and j;) R1 and R2 taken together with the linking nitrogen represent;
N-tetrahydroquinolyl or N-tetrahydroisoquinolyl;
and the pharmaceutically acceptable salts thereof.
WO 94/25466 21~1~ 8 ~ -6- PCT/US94/04681~
Another sub group of compounds of the present invention are the compounds of formula (I) wherein:
n represents the integer 1 or 2; and i) R1 represents:
hydrogen, (C1 3) alkyl or amino (C1 3) alkyl; and R2 represents:
diphenylmethyl or(CH2)tAr;
1 0 wherein:
tis 1 to3and Ar represents phenyl, 2-furyl, 2-pyridyl, 4-pyridyl 2-N-methylpyrrolyl, 4-imidazolyl; or phenyl, 2-furyl, 2-pyridyl, 4-pyridyl, 2-N-methylpyrrolyl, 4-imidazolyl, with one to two substituents selected from hydroxy, methoxy, halogen, and amino; or ii) R1 and R2 taken together with the linking nitrogen represent N-tetrahydroisoquinolyl;
and the pharmaceutically acceptable salts thereof.
In one particular group of compounds of formula (I) Ar represents phenyl, furyl,pyridyl, N-methylpyrrolyl, imidazolyl or phenyl substituted with one or two 25 substituents independently selected from hydroxy, methoxy, halogen and amino.Typical Ar groups include phenyl and substituted phenyl, 2-furyl, 2-pyridyl, 4-pyridyl, 2-N-methylpyrrolyl and 4-imidazolyl. In one particular subgroup of compounds of formula (I), Ar is substituted phenyl or 4-pyridyl.
In another subgroup of compounds R1 represents hydrogen, lower alkyl, lower alkylaminolower alkyl or -(CH2)tAr, especially hydrogen or lower alkyl.
In another subgroup of compounds of formula (I), t is 1, 2, or 3, especially 1 and n is 1 or 2, especially 2.
Specific compounds of formula (I) are:
~0 94/2s466 PCT/US94/04681 -7- - r~
Example Number Compound Name 1. 7-(N-Ethyl-N-4-pyridylmethyl)- aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 2. 7-(4-Aminobenzyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 3. 7-(3-Methoxy-4-hydroxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 10 4. 7-Benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 5. 7-(N-Tetrahydroisoquinolino)methylene-10, 11-ethylenedioxy-20(S)-camptothecin, 6. 7-Dibenzylaminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 7. 7-(N-Methyl)benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 8. 7-Furylaminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 9. 7-(3-Phenylpropyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 10. 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 11. 7-(N-Ethyl, (2-chloro-6-fluorobenzyl))-aminomethylene-10, 11-ethylenedioxy- 20(S)-camptothecin, 12. 7-(3,4-Difluorobenzyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 13. 7-Diphenylmethylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 14. 7-((R) 1 -Phenylethyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 15. 7-((S) 1-Phenylethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 16. 7-(2(N-Methyl-2-pyrrol)-ethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 17. 7-(N-benzyl-N-(2-Dimethylaminoethyl)-aminomethylene-10, 11 -" ethylenedioxy-20(S)-camptothecin, 18. 7-(2-(4-lmidazolyl)ethyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 19. 7-(2-Pyridylmethyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 20. 7-Benzylaminomethylene-10, 11-methylenedioxy-20(S)-camptothecin, and 216168~
21. 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11-methylenedioxy-20(S)-camptothecin, and pharmaceutically acceptable salts and solvates thereof.
Particular specific compounds of formula (I) are:
7-(N-Ethyl-N-4-pyridlymethyl)- aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(4-Aminobenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-1 0 camptothecin, 7-(3-Methoxy-4-hydroxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, and pharmaceutically acceptable salts and solvates thereof.
Prep~ration of Compounds According to one general process (A), compounds of formula (I) may be 20 prepared by the procedure shown in Step 2 of Scheme l:
~VO 94125466 2161 ~8 1 PCT/US94/04681 \N ~
(CH2)~0 ~ ~
( 11 ) / H 60 <
(V) ~
( ) / OH ~o SCHEME I
In Step 1 of Scheme 1, a compound of formula (Il), wherein X is a leaving group (as defined in J. March, Advanced Organic Chemistry, 3rd. Ed., page 179, 5 John Wiley & Sons, New York (1985)), for example, a halogen, e.g., chloro, may be reacted with a compound of formula (Ill) according to the method taught in US
Patent 4,894,456 (hereinafter, '456), issued January 16, 1990 to Wall et al., incor-porated herein by reference, to yield a compound of formula (IV).
The reaction of Step 1 is preferably carried out in the presence of an acid or base catalyst. The acid catalyst is preferably a strong mineral acid, for example hydrochloric, nitric, sulfuric and phosphoric or a strong organic acid such as C1-8 alkanoic acids and C1.12 arylsulfonic acids, especially p-toluenesulfonic acid. The base catalyst is preferably an inorganic base, for example sodium and potassium 1~ carbonate and sodium and potassium bicarbonate or an organic base such as a WO 94/25466 21~ 16 8 1 1o- PCT/US94/04681--sterically hindered base, for example, triethylamine and diisopropylamine.
This reaction may be carried out neat or in the presence of a polar or non-polar solvent. Preferred polar solvents are C1.6 alcohols, C1-6 ethers, and 5 dimethylformamide. Preferred non-polar solvents are branched or straight chained alkyl hydrocarbons having 4-10 carbon atoms and aromatic hydrocarbons having 6-20 carbon atoms especially toluene. The reaction is generally conducted with heating at reflux.
In Step 2, (General Process A) the compounds of formula (IV) may be converted to the compounds of formula (I) by displacement of the leaving group, X, with a compound of formula (V), wherein R1 and R2 are as defined for formula (I).
This displacement reaction may conveniently be carried out in a solvent system, for example water, a (C1 4) alkanol, a (C2 4) alkylene diol, 1-hydroxy-2-15 methoxyethane, dimethylacetamide (DMAC), N-methylpyrolidinone, dimethyl for-mamide (DMF), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), toluene, dioxane or a combination of these solvents in the presence of excess amine, i.e., excess compound of formula (V), with or without a base, e.g., potassium carbonate, and/or with Nal as a catalyst.
This method is particularly useful for preparing compounds of formula (I) wherein R1 is other than hydrogen.
Compounds of formula (V) are commercially available, taught in the chemical 25 literature, or may be readily prepared by one skilled in the art of organic chemistry using methods and materials known in the art of organic chemistry.
According to another general process (B), compounds of formula (I) may be prepared by the procedure shown in Step 2a of Scheme IA:
WO 94/2~i466 81 PCT/US94/04681 (CH2)~
b NH2 HNR1R2 ~ ( 11 ) ( V ) ~/Step 1a ~ o (IIA) (1ll) s~p 2a / OH ~b y ~-o OH
In Step 1a, a compounds of formula (Il) may be converted to a compounds of formula (IIA) by displacement of the leaving group, X (as defined for Scheme 1), with 5 a compound of formula (V), wherein R1 and R2 are as defined for formula (I). This displacement reaction may conveniently be carried out in a solvent system, for example, water, a (C14) alkanol, a (C2.4) alkylene diol, 1-hydroxy-2-meth-oxyethane, dimethylacetamide (DMAC), N-methylpyrolidinone, dimethyl formamide (DMF), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), toluene, dioxane or a 10 combination of these solvents (to the extent of miscibility) in the presence of excess amine, i.e., excess compound of formula (V), with or without a base, e.g., potassium carbonate, and/or with Nal as a catalyst.
In Step 2a (General Process B), compound of formula (IIA) is reacted with a 15 compound of formula (Ill) in a similar manner to that taught above in Scheme 1, Step 1, to yield a compound of formula (I).
WO 94/25466 2 1 6 1 6 8 1 -12- PCT/US94/0468~
Further alternate general method (C), particularly useful for preparing compounds of Formula (I) wherein R1 is hydrogen, is shown in Step 3b of Scheme x /~o (CH2)~NH2 D~ ~ (11) (Hal)3C~ NHR ~/ SteP lb C~ 2 I \N
\~NH~ OH~O
(llb) ~ (1ll) (Hal)30~0 ~NR2 H'B- / OH 6 Step 3b NR~ B-O C
(Ib) 2l~l68l ~VVO 94/25466 PCTfUS94tO4681 ln Step lb, a compound of formula (Va) (wherein "Hal" is halogen, i.e., fluoroj chloro, bromo or iodo) e.g., trifluoroacetamide, is reacted with a compound of for-mula (Il) in a polar, aprotic solvent, e.g., acetonitrile, in the presence of a base sol-uble in the polar, aprotic solvent, e.g., cesium carbonate if the solvent is acetonitrile, 5 to yield a compound of formula (llb).
In Step 2b, a compound of formula (llb) is reacted with a compound of formula (Ill) in a similar manner to that taught in Scheme 1, Step 1, to yield a compound of formula (IVb).
In Step 3b (General Process C), a compound of formula (IVb) is treated with an acid, H+B-, such as a mineral acid, e.g., hydrochloric acid, to yield a compound of formula (Ib), i.e. salt of a compound of formula (I). The compound of formula (Ib) may be treated with a base, such as an alkali metal hydroxide or carbonate, e.g., 15 sodium hydroxide or potassium carbonate, by standard method of the art to yield the corresponding free base. For example a compound of formula (Ib) may be stirred with an aqueous solution of potassium carbonate for about one to about four hours in the temperature range of from about 5 to about 100C. The free base can then be converted by conventional means to a pharmaceutically acceptable 20 salt if required.
The compounds of formula (Il) and (Ill) may be prepared according to the procedure described in EP0 540 099 A1.
The novel, intermediate compounds of formulas (lla), (llb) and (IVb) are within the scope of this invention.
A compound of formula (I) according to the invention may be converted into another compound of the invention using conventional procedures.
Thus, for example, a compound of formula (I) wherein R1 represents a hydrogen atom, may be alkylated using conventional techniques. The reaction may be effected using a suitable aklylating agent such as an alkyl halide, an alkyl tosylate or a dialkylsulphate. The alkylation reaction may conveniently be carried out in an organic solvent such as an amide, e.g. dimethylformamide, or an ether,e.g. tetrahydrofuran, preferably in the presence of a base. Suitable bases include, for example, alkali metal hydrides, such as sodium hydride, alkali metal carbonates, such as sodium carbonate, or potassium methoxide, ethoxide or t-butoxide. The alkylation reaction is conveniently carried out at a temperature of 21616~1 from about 25 to about 1 00C.
Alternately, a compound of formula (I) wherein R1 represents a hydrogen atom may be converted to another compound of formula (I) by reductive alkylation.
5 Reductive alkylation with an appropriate aldehyde or ketone may be effected using an alkaline earth metal borohydride or cyanoborohydride. The reaction medium, co~veniently in an alcohol, e.g. methanol or ethanol or an ether, e.g. dioxan ortetrahydrofuran, optionally in the presence of water. The reaction may conveniently be carried out at a temperature in the range of 0 to 100C, preferably about 5 to 10 about 50C.
Alternatively, a compound of formula (I) wherein R1 represents a lower alkenyl group may be converted to another compound of formula (I) wherein Rl represents a lower alkyl group. Reduction may conveniently be effected in the presence of 15 hydrogen and a metal catalyst, for example, Raney nickel or a nobel metal catalyst such as palladium, platinum, platinum oxide or rhodium, which may be supported, for example, on charcoal. The reaction may be effected in a solvent such as an alcohol, for example ethanol and conveniently at a temperature of from about -10 to about +50C, preferably about 20 to about 30C.
A compound of formula (I) according to the invention, or a salt thereof may br prepared by subjecting a protected derivative of formula (I) or a salt thereof to reac-tion to remove the protecting group or groups.
Thus, at an earlier stage in the preparation of a compound of formula (I) or a salt thereof it may have been necessary and/or desirable to protect one or more sensitive groups in the molecule to prevent undesirable side reactions.
The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See for example, "Protective Groups in Organic Chemistry~ Ed. J.F.W. McOmie (Plenum Press 1973) or "Protective Groups in Organic Synthesis" by Theodora W. Greene (John Wiley and Sons 1981).
Conventional amino protecting groups may include, for example, aralkyl 3~ groups, such as benzyl, diphenylmethyl or triphenylmethyl groups; and acyl groups such as N-benzyloxycarbonyl or t-butoxycarbonyl. Thus, compounds of general formula (I) wherein R1 represents hydrogen may be prepared by deprotection of a corresponding protected compound.
~vo 94/25466 -15- ~681 PcT/uss4/046s1 Hydroxy groups may be protected, for exampie, by aralkyl groups, such as benzyl, diphenylmethyl or triphenylmethyl groups, acyl groups, such as acetyl, sili-con protecting groups, such as trimethylsilyl or t-butyl dimethylsilyl groups or as tetrahydropyran derivatives.
Removal of any protecting groups present may be achieved by conventional procedures. Thus, an aralkyl groups such as benzyl, may be cleaved by hy-drogenolysis in the presence of a catalyst (e.g. palladium on charcoal); an acylgroup such as N-benzyloxycarbonyl may be removed by hydrolysis with, for ex-ample, hydrogen bromide in acetic acid or by reduction, for example by catalytichydrogenation; silicon protecting groups may be removed, for example, by treat-ment with fluoride ion or by hydrolysis under acidic conditions; tetrahydropyrangroups may be cleaved by hydrolysis under acidic conditions.
As will be appreciated, in any of the processes described above, it may be necessary or desired to protect any sensitive groups in the molecule as just de-scribed. Thus, a reaction step involving deprotection of a protected derivative of general formula (I) or a salt thereof may be carried out subsequent to any of the above described processes.
Thus, according to a further aspect of the invention, the following reactions may, if necessary and/or desired by carried out in any appropriate sequence sub-sequent to any of the processes (i) removal of any protecting groups; and (ii) conversion of a compound of formula (I) or a salt thereof into a pharmaceutically acceptable salt thereof.
Where it is desired to isolate a compound of the invention as a salt, for exam-ple, as an acid addition salt, this may be achieved by treating the free base of gen-eral formula (I) with any appropriate acid, preferably with an equivalent amount, or with creatinine sulphate in a suitable solvent (e.g. aqueous ethanol).
As well as being employed as the last main step in the preparative sequence, the general methods indicated above for the preparation of the compounds of the invention may also be used of the introduction of the desired groups at an inter-mediate stage in the preparation of the required compound. It should therefore be appreciated that in such multi-stage processes, the sequence of reactions shouldbe chosen in order that the reacting conditions do not affect groups present in the WO 94/25466 2 ~ 6 1 6 81 PCT/US94/04681~
molecule which are desired in the final product.
The biological activity of the compounds of formula (I) appears to reside in theS enantiomer, and the R enantiomer has little or no activity. Thus, the S enan-5 tiomer of a compound of formula (I) is generally preferred over a mixture of R and Ssuch as the racemic mixture. However, if the R enantiomer were desired, e.g., for control studies or synthesis of other compounds, it could be conveniently prepared by the procedure above using the R enantiomer of the compound of formula (Ill) prepared according to the teachings of '512.
A compound of formula (I) prepared by reaction Scheme I or Scheme IA may be purified by conventional methods of the art, e.g., chromatography, distillation or crystallization.
15 Cle~vable Complex 7n vitro Assay The data in Table A, below, shows the relative topoisomerase Type I inhibitory activity of the compounds of Formula (I). This assay performed according to the method described in Hsiang, Y. et al., J. Blol. Chem., 260:14873-14878 (1985), 20 correlates well with in vivo anti-tumor activity of topoisomerase inhibitors in animal models of cancer, e.g., camptothecin and its analogs. See Hsiang et al., Cancer Research, 49:4385-4389 (1989) and Jaxel et al., Cancer Research, 49:146~-1469 (1989).
Those compounds which exhibit observable activity at concentrations greater 25 than 2000 nM ("+~ in Table A) are considered weakly to moderately active, while those with activity at concentrations less than 500 nM (U++++~ in Table A) are very active. The term ~ICsoU means the concentration of a compound of formula (I) at which 50% of the DNA substrate has been captured by topoisomerase 1.
TABLE A
Topoisomerase Inhibitory Activity of Compounds of Formula (I) in the Cleavable Complex Assay Example Isomeric Relative Number form 4 (S) 1 l l l 8 (S) ++++
(S) m 11 14 (S) ~+++
(S) ++++
~0 94/2~466 -17- ~1 PCT/US94/04681 16 (S) ++++
21 (S) ++++
2 (S) ++++
19 (S) ++++
3 (S) ++++
(S) +It I
18 (S) ++++
6 (S) +++
7 (S) +++
(S) +++
12 (S) +++
17 (S) +++
(S) ++
11 (S) ++
13 (S) ++
9 (S) ++
ICso Range Symbol nM
++++ <~500 +++ <~ 1000~~500 ++ <~2000>~ 1000 + >~2000 Utility In view of such activity, the compounds of formula (I) are active against a widespectrum of mammalian (including human) tumors and cancerous growths such as cancers of the oral cavity and pharynx (lip, tongue, mouth, pharynx), esophagus,stomach, small intestine, large intestine, rectum, liver and biliary passages, pan-30 creas, larynx, lung, bone, connective tissue, skin, colon, breast, cervix uteri, corpusendometrium, ovary, prostate, testis, bladder, kidney and other urinary tissues, eye, brain and central nervous system, thyroid and other endocrine gland, leukemias (Iymphocytic, granulocytic, monocytic), Hodgkin's disease, non-Hodgkin's Iym-phomas, multiple myeloma, etc. Hereir~ the terms utumor", Ucancer" and "cancerous 35 growthsU are used synonymously.
The amount of compound of formula (I) required to be effective as an antitu-mor agent will, of course, vary with the individual mammal being treated and is ul-timately at the discretion of the medical or veterinary practitioner. The factors to be 2~ 6~ .
W094/25~6 PCT~S94/0~81 . -18-considered include the condition being treated, the route of administration, the na-ture of the formulation, the mammal's body weight, surface area, age and generalcondition, and the particular compound to be administered. However, a suitable effective antitumor dose is in the range of about 0.1 to about 200 mg/kg body 5 weight per day, preferably in the range of about 1 to about 100 mg/kg per day. The total daily dose may be given as a single dose, multiple doses, e.g., two to six times per day, or by intravenous infusion for a selected duration. Dosages above or be-low the range cited above are within the scope of the present invention and may be administered to the individual patient if desired and necessary.
For example, for a 75 kg mammal, a dose range would be about 75 to about 7500 mg per day, and a typical dose would be about 800 mg per day. If discrete multiple doses are indic~te~, treatment might typically be 200 mg of a compound of formula (I) given 4 times per day.
Formul~tions Formulations of the present invention, for medical use, comprise an active compound, i.e., a compound of formula (I), together with an acceptable carrier therefof and optionally other therapeutically active ingredients. The carrier must be pharmaceutically acceptable in the sense of being compatible with the other in-gredients of the formulation and not deleterious to the recipient therefor.
The present invention, therefore, further provides a pharmaceutical formula-tion comprising a compound of formula (I) together with a pharmaceutically accept-able carrier thereof.
The formulations include those suitable for oral, rectal or parenteral (including subcutaneous, intramuscular and intravenous) administration. Preferred are those suitable for oral or parenteral administration.
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methodsinclude the step of bringing the active compound into association with a carrierwhich constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into asso-ciation with a liquid carrier or a finely divided solid carrier and then, if necessary, shaping the product into desired unit dosage form.
~WO 94/25466 6~7~81 PCT/US94/04681 Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, eachcontaining a predetermined amount of the active compound; as a powder or gran-ules; or a suspension or solution in an aqueous liquid or non-aqueous liquid, e.g., 6 a syrup, an elixir, an emulsion or a draught.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form, e.g., a powder or 10 granules, optionally mixed with accessory ingredients, e.g., binders, lubricants, in-ert diluents, surface active or dispersing agents. Molded tablets may be made bymolding in a suitable machine, a mixture of the powdered active compound with any suitable carrier.
A syrup or suspension may be made by adding the active compound to a concentrated, aqueous solution of a sugar, e.g., sucrose, to which may also be added any accessory ingredients. Such accessory ingredient(s) may include flavor-ing, an agent to retard crystallization of the sugar or an agent to increase the solu-bility of any other ingredient, e.g., as a polyhydric alcohol, for example, glycerol or 20 sorbitol.
Formulations for rectal or vaginal administration may be presented as a sup-pository with a conventional carrier, e.g., cocoa butter or Witepsol S55 (trademark of Dynamite Nobel Chemical, Germany, for a suppository base).
For transdermal administration, the compounds according to the invention may be formulated as creams, gels, ointments or lotions or as a transdermal patch.
Such compositions may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening, gelling, emulsifying, stabilizing, dispersing, 30 suspending and/or coloring agents.
Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the recipient. Such formulations suitably comprise a solution or 35 suspension of a pharmaceutically and pharmacologically acceptable acid addition salt of a compound of the formula (I) that is isotonic with the blood of the recipient.
Thus, such formulations may conveniently contain distilled water, 5% dextrose indistilled water or saline and a pharmaceutically and pharmacologically acceptable acid addition salt of a compound of the formula (I) that has an appropriate solubility WO 94/2~466 2~ 681 -20- PCTIUS94/04681~
in these solvents, for example the hydrochloride. Useful formulations also com-prise concentrated solutions or solids containing the compound of formula (I) which upon dilution with an appropriate solvent give a solution suitable for parental ad-ministration above.
In addition to the aforementioned ingredients, the formulations of this inven-tion may further include one or more optional accessory ingredient(s) utilized in the art of pharmaceutical formulations, e.g., diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, suspending agents, preservatives 10 (including antioxidants) and the like.
EXAM PLES
The following examples illustrate aspects of this invention but should not be 15 construed as limitations. The symbols and conventions used in these examples are consistent with those used in the contemporary chemical literature, for example, the Journal of the American Chemical Society. As used here in the term "room temperature" means about 25C.
GENERAL PRO~:EDURE
A flask is charged with (S)-7-chloromethyl-10,11-ethylenedioxycamptothecin (25-150 mg, 0.06-0.33 mmol), catalytic sodium iodide (1-15 mg, 99.99% Aldrich), and anhydrous 1,4-dioxane (2-50 mL). The amine is added (2-5 equiv. neat), and 25 the stirred slurry was heated in an oil bath at 75-95 C. The reaction was moni-tored for disappearance of starting material by thin layer chromatography. The mixture is worked up by removing the solvent with a rotary evaporator, and triturat-ing the residue with ether. The solid that is collected by suction filtration is purified by silica gel chromatography or reverse phase HPLC (Rainin Dynamax 60A col-30 umn, eluting with 2% trifluoroacetic acid in water (70-80%) and 4:1 acetonitrile THF
(20-30%), monitoring at 254 nm) to afford the product amine as either the free base or the trifluoroacetic acid salt respectively.
WO 94/25466 `, 61~i681 PCT/US94/04681 F~ample 1 7-(N-Fthyl-N-4-pyridylmethyl)- ~minomethylene-10. 11 -ethylenedioxy-20(S)-cam~ ptothecin (Compound 1) (A) 6'-amino-3',4'-ethylenedioxy-2-chloroacetophenone A 1-L, three-necked, round-bottomed flask was fitted with a magnetic stirring bar, thermometer, reflux condenser with calcium chloride filled drying tube, and a nitrogen inlet. The reaction vessel was charged with dry methylene chloride (10010 ml) and 1,4-benzodioxane-6-amine (15.12 9, 100 mmol). The reaction vessel wascooled to 0 C followed by slow addition of 400 ml of a lM solution of boron trichloride in methylene chloride while maintaining an internal temperature at or below 10C. Aluminum chloride (13.34 9, 100 mmol) was added quickly in three portions followed by addition of chloroacetonitrile (7 ml, 110 mmol). The reaction 15 was stirred for 30 min at 0 C then heated to 40C for 16 hours. The reaction was removed from heat, allowed to cool to room temperature, then quenched into a mixture of 1 kg of ice/ 500 ml of lN HCI. The mixture was stirred until no solids were observed. The methylene chloride layer was removed and the aqueous layer was extracted twice with methylene chloride. The organic layers were combined, 20 washed with brine, dried over magnesium sulfate, filtered, treated with decolorizing carbon, filtered through a pad of celite, and concentrated to a solid residue. The solid was recrystallized from ethyl acetate/hexanes to give 8.3 g (36.5%) of 6'-amino-3',4'-ethylenedioxy-2-chloroacetophenone.
MS (Cl): m/z 228 (M+H+).
1 H NMR (CDCI3):â 7.14 (s, lH), 6.15 (s, 1 H), 4.57 (s, 2H), 4.3 (m, 2H), 4.2 (m, 2H), 1.6 (s, broad, 2H).
Anal. (CloHloclNo3) calc. found C 52.76 52.66 H 4.43 4.53 7-Chloromethyl-10,11-ethylenedioxy-20(S)-camptothecin. Into a 250 ml round-30 bottomed flask equipped with a stirring bar, a reflux condeser and a Dean Stark WO 94/2~466 2 I 6 1 ~ 8 1 PCT/US94/04681--trap were added 1.82 9 (8.0 mmol) of 2'-amino-4',5'-ethylenedioxy-2-chloroacetophenone, 40 ml dry toluene and 2.0 g (7.6 mmol) of (S) tricyclic keto-lactone. The reaction was stirred under nitrogen and refluxed for 0.5 hours. Thereaction was allowed to cool followed by addition of 100 mg, (0.~3 mmol) of p-5 toluenesulfonic acid. The reaction was then heated to reflux for 36 hours. Thereaction was cooled, and the solids were collected by filtration and washed withtoluene followed by thorough washings of the solids by anhydrous ethanol. The remaining greenish-brown solid was dried under vacum at room temperature yielding 2.67 9 (77.2%) of > than 97% pure materal.
1H NMR (DMSO-d6): ~ 7.47 (s,1H), 7.32 (s, 1H), 6.98 (s, 1H), 5.15 (s, 1H), 5.06 (s, 1H), 4.97 (s, 1H), 4.19 (s, 4H), 2.23 (s, 2H), 1.6 (m, 2H), 0.68 (m, 3H).
MS M+H = 455.
HRMS: Calc. 455.1009; Found 455.1000.
Anal. (C23H1gN2ClO6) C, H
calc. found C 60.73 60.70 H 4.21 4.30 (C) 7-(N-Ethyl-N-4-pyridylmethyl)- aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin A flask is charged with (S)-7-chloromethyl-10,11 -ethylenedioxycamptothecin (0.60 g,1.3 mmol), catalytic sodium iodide (20 mg, 99.99% Aldrich), and anhydrous 20 1,4-dioxane (120 mL). The 4-(ethylaminomethyl)pyridine (0.54 g, 4.0 mmol) is added and the stirred slurry was heated in an oil bath at 75-95 C. The reactionwas monitored for disappearance of starting material by thin layer chromatography.
The mixture is worked up by removing the solvent with a rotary evaporator, and triturating the residue with ether. The solid that is collected by suction filtration is 25 purified by reverse phase HPLC (Rainin Dynamax 60A column, eluting with 2%
trifluoro~cetic acid in water (70-80%) and 4:1 acetonitrile:THF (20-30%), monitoring at 254 nm) to afford the product amine as the trifluoroacetic acid salt.
Mp 178-180C.
W094125466 ~ 681 PCl/US94/04681 FAB MS MH+ 555.
1H NMR (d6-DMSO) ~ 8.58(d, 2H), 7.83(s, lH), 7.58(d, 2H), 7.52(s, 1H), 7.24(s, 1H), 5.42(s, 2H), 5.31(s, 2H), 4.46(s, 4H), 4.15(br s, 2H), 3.79(br s, 2H), 2.65(m, 2H), 1.86(m, 2H), 1.16(t, 3H), 0.87(t, 3H).
FxamDle 2 7-(4-aminobenzyl)aminomethyl-10.11 -ethylenedioxy-(20S)-camptothecin (ComDound ~) A flask is charged with 7-chloromethyl-10,11-ethylenedioxy-(20S)-camptothecin (252 mg, 0.555 mmol), Nal (42 mg, 0.307 mmol) and anhydrous 1,4-dioxane (2-50 mL). 4-Aminobenzylamine (192 mL, 207 mg, 1.7 mmol), is added and the stirred slurry is heated in an oil bath at 75-95 C. The reaction is monitored for disappearance of starting material by thin layer chromatography. The mixture is 15 worked up by removing the solvent with a rotary evaporator, and triturating the residue with ether. The crude product is collected by suction filtration and purified by flash chromatography (eluting with 6:5:1 EtOAc/CHCI3/MeOH) to afford the amine product which was further purified by recrystallizing from t-butylmethyl ether to afford 100.6 mg (34% yield) of pure product. The TLC salt was formed by 20 dissolving in 2% aqueous trifluoroacetic acid and Iyophylizing to afford the product TFA salt (141.4 mg) as a bright yellow solid, mp 280 C (dec).
1H NMR (300 MHz, DMSO-d6): ~ 0.85 (t, 3H, J=7.1), 1.78-1.95 (m, 2H), 4.27 (bs, 1H), 4.45 (s, 2H), 4.65 (bs, 1H), 5.42 (s, 2H), 6.63 (d, 1H, J=8.30), 7.21 (d, 1H, J=8.30), 7.27 (s, 1 H), 7.63 (s, 1 H), 7.75 (s,1 H), 9.05 (bs, 2H).
25 Low resolution ms (M+1): 541.3 (calcd 541).
Anal. Calcd C30H2gN4O8-2TFA-2.5H2O:
calc. found C 48.23 48.25 H 4.22 4.18 N 6.43 6.39.
wo 94/2~466 ' -24- PCT/US94/04681 Fxample 3 7-(3-Methoxy-4-hydroxyben7yl)-aminomethylene-10. 11-ethylenedioxy-~O(S)-5 ~rnptothecin (Compound 3) A flask is charged with (S)-7-chloromethyl-10,11-ethylenedioxycamptothecin ( 250mg, 0. 549 mmol), catalytic sodium iodide ( 20 mg, 99.99% Aldrich), and anhydrous 1,4-dioxane (25 mL). 4-Hydroxy-3-methoxybenzylamine is added ( 254 mg,1.66 mmol neat), and the stirred slurry was heated in an oil bath at 75-95 C for 18h.
10 The reaction was monitored for disappearance of starting material by thin layer chromatography. The mixture is worked up by removing the solvent with a rotary evaporator, and triturating the residue with ether. The solid that is collected by suction filtration is purified by reverse phase HPLC (Rainin Dynamax 60A column,eluting with 2% trifluoroacetic acid in water (70-80%) and 4:1 acetonitrile THF (20-15 30%), monitoring at 254 nm) to afford the product amine as the trifluoroacetic acidsalt 214 mg (68%).
MS (FAB ) (M+H) +572.3.
1H NMR (DMSO-d6): o 7.74 (s,1H), 7.63 (s,1H), 7.28 (s,1H), 7.24 (br s,1H), 6.95 (d,1H,j=8Hz), 6.82 (d,1H,j=8Hz), 5.42 (s,2H), 4.68 (br s,1H), 4.46 (br s,2H), 4.35 (br 20 s,1H), 3.78 (s,3H), 1.86 (m,2H), 0.85 (t,2H).
Fxamples 4-~1 The following compounds of formula (I) are prepared by the procedure taught 25 in Scheme 1, in an analogous manner to Example 1 using the appropriate intermediate compounds of formulas (Il), (Ill), and (V).
4. 7-Benzylaminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, (as the trifluoroacetic acid (TFA) salt) 30 Nominal mass spectrum: MH+526, mp = >300C (decomposition).
5. 7-(N-tetrahydroisoquinolino)methylene- 10, 11 -ethylenedioxy-20(S)-camptothecin, (as TFA salt) 35 Nominal mass spectrum: MH+552, mp = 265-270C.
WO 94/25466 6'~1 PCT/US94/04681 6. 7-Dibenzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+630, mp = 180C (decomposition).
7. 7-(N-Methyl)benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+540, mp = 205C (decomposition).
BACKGROUND OFTHE INVENTION
Camptothecin, a natural, cytotoxic a~kaloid, is a topoisomerase I inhibitor and 10 potent antitumor agent. It was first isolated from the leaves and bark of the Chinese plant, Camptotheca accuminata, by Wall, et. al. (J. Am. Chem. Soc., 88 3888 (1 966)).
As depicted, camptothecin is a fused ring system, composed of a quinoline (A
15 and B), fused to a pyrrolidine ring (C), fused to an alpha-pyridone ring (D) which in turn is fused to a lactone ring (E).
CAMPTOTHECIN
~
20 It has an asymmetric carbon at the 20 position making two enantiomeric forms possible. However, the natural occurring compound is found in the "S" configura-tion as shown above.
Cytotoxic agents are often employed to control or eradicate tumors i.e., they 25 are chemotherapeutic agents. Camptothecin's cytotoxic activity is thought to be di-rectly related to camptothecin's potency as a topoisomerase inhibitor. [For detailed explanations of the topoisomerase function see A. Lehninger, Principles of Biochemisfry, 813, Worth Publishers, New York (1982); L. F. Liu, "DNA
Topoisomerases," CRC Critical Review in Biochemistry, 1-24,15 (1983) and H
30 Vosberg, ~DNA Topoisomerases: Enzymes that Control DNA Conformation,"
Current Topics in Microbiology and Immunology, 19, Springer-Verlag, Berlin 2 ~ 8 l WO 94/2~466 PCT/US94/04681 (1985).] In particular, camptothecin has been shown to be effective in the treatment of leukemia (L-1210) and certain solid tumors in laboratory animals, e.g., see Chem. Rev. 23, 385 (1973) and Cancer Treaf. Rep., 60, 1007 (1967).
Unfortunately, in the ciinic camptothecin's promise as an effective antitumor agent has not bee~ completely fulfilled. Camptothecin is essentially insoluble in physiologically compatible, aqueous media, and must be modified to make it suffi-ciently soluble for parenteral administration, a preferred mode for antitumor treat-ment. It can be made soluble by forming its sodium salt, that is, by opening thelactone with sodium hydroxide (see F.M. Muggia, et al., Cancer Chemotherapy Reports, pt. 1, 56, No.4, 515 (1972)). However, M. C. Wani, et al., J. Med. Chem., 23, 554 (1980), reported that the alpha-hydroxy lactone moiety of ring E is an abso-lute requirement for antitumor activity.
In the art there are examples of modifications and derivatives of camptothecin prepared to improve its solubility in water. Although many of these derivatives were active in vitro and in early animal studies using leukemia (L-1210) models, theywere disappointing in chronic, animal models involving implanted solid tumors.
Miyasaka, et al., U.S. Patent No. 4,399,282, discloses a group of camptothecin derivatives substituted at the 7 position with, inter alia, hydroxymethyl and alkoxymethyl. Further, Miyasaka, et. al. in U.S. patent No. 4,399,276 discloses camptothecin-7-aldehyde and certain related aldehyde derivatives such as acetals, oximes and hyrazones. More recently, Vishnuvajjala, et al., in U.S. Patent No.
4,943,579, claimed a series of water-soluble camptothecin derivatives with sub-stituents on the A ring as does Boehm, et al., European Patent Application 0 321122 A2. Other examples of derivatives of camptothecin include Miyasaka, et al., U.S. Patent No. 4,473,692 and No. 4,545,880; and W. Kingsbury, et al., J Med.
Chem., 34, 98 (1991). None of these references reported compounds with antitu-mor activity greater than that of camptothecin itself.
Wani and co-workers reported that 10, 11-methylenedioxycamptothecin is more potent than unsubstituted camptothecin (see M. C. Wani, et al., J. Med. Chem, 29, 23~8 (1986) and 30, 2317 (1987)). However, its water solubility is as poor as camptothecin which seriously limits its clinical utility.
We have now found water-soluble analogs of camptothecin with good topoi-somerase I inhibitory activity in vitro, and impressive, antitumor activity in vivo.
21 61 ~81 ~0 94125466 PCT/US94/04681 SUMMARY OF THE INVENTION
One aspect of the present invention is the water-soluble camptothecin analogs of formula (I), , ~
(~
OH
wherein:
n represents the integer 1 or 2; and i) R1 represents:
hydrogen, lower alkyl, (C3 7)cycloalkyl, (C3 7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkylamino lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr 1 5 wherein:
t is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl, with one or more substituents independently selected from hydroxy, methoxy, halogen, and amino;
and R2 represents:
diphenylmethyl or(CH2)tAr; or ii) R1 and R2 taken together with the linking nitrogen represent;
N-tetrahydroquinolyl or N-tetrahydroisoquinolyl;
and the pharmaceutically acceptable salts and solvates thereof.
Pharmaceutically acceptable salts include, but are not limited to salts with in-organic acids such hydrochloride, sulfate, phosphate, diphosphate, hydrobromide 216168~
WO 94/2~i466 PCT/US94/04681--and nitrate or salts with an organic acid such as acetate, malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, palmoate, salicylate and stearate. Other acids such as oxalic, while not in themselves phar-maceutically acceptable, may be useful as intermediates in obtaining the com-5 pounds of the invention and their pharmaceutically acceptable salts.
Another aspect of the invention is a method of inhibiting topoisomerase Type I
in mammalian cells comprising àdministering to a patient a topoisomerase inhibit-ing amount of a compound of formula (I), and a method of treating a tumor in a 10 mammal comprising administering to a mammal bearing a tumor, an effective anti-tumor amount of a compound of formula (I). A further aspect comprises pharma-ceutical formulations containing a compound of formula (I) as an active ingredient.
Methods of preparation of the compounds of formula (I) and the associated novel chemical intermediates used in the synthesis, as taught herein, are also within the 15 scope of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
Compounds As used herein the term "lower" in reference to alkyl and alkoxy means 1-6 carbons, especially 1-3 carbons, and in reference to alkenyl means 3-6 carbons (provided that the double bond is not attached to the carbon which is attached to the nitrogen). As use herein, the term ~arylU means aromatic ring substituents, e.g., 25 phenyl, napthyl, furyl, pyridyl, N-methylpyrrolyl or imidazolyl. The group "(CH2) also includes branched alkylene chains where branching is possible.
As use herein the terms "N-tetrahydroquinolyl" and "N-tetrahydroisoquinolyl"
are defined as follows:
N-tetrahydroquinolyl N-tetrahydroisoquinolyl The lactone ring, i.e., ring E, of the camptothecin moiety may be opened by 35 alkali metal or alkaline-earth metal bases, for example sodium hydroxide or calcium hydroxide, to form alkali metal or alkaline-earth metal salts of the 21 6l 68l ~WO 94/2~466 PCTIUS94/04681 corresponding open E ring form of the compounds of formula (1). Because of its better solubility in water, the open E ring form may advantageously be purified by conventional recrystallization techniques. Accordingly, said open E ring form may then be used as an intermediate to form the compounds of formula (1), for example 5 by treatment with acid, e.g., hydrochloric acid, and thereby produce a purified form of the compounds of formula (1).
As noted above, the camptothecin moiety has an asymmetric carbon atom at the 20 position making two enantiomeric forms, i.e., UR" and "S" configurations,possible. This invention includes both enantiomeric forms and any combinations of these forms. For simplicity, where no specific configuration at the 20 position is depicted in the structural formulas, it is to be understood that both enantiomeric forms and mixtures thereof are represented. Unless noted otherwise, the nomen-clature convention, ''(R,S)U, denotes a racemic (approximately equal portion) mix-ture of the R and S enantiomers while ~(R)u and "(S)" denote essential opticallypure R and S enantiomers respectively. Also included in the invention are other forms of the compound of formula (1), such as solvates, hydrates, polymorphs andthe like.
One sub group of compounds of the present invention are the compounds of formula (I) wherein:
n represents the integer 1 or 2; and j) R1 represents:
hydrogen, lower alkyl, (C3 7)cycloalkyl, (C3 7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr wherein:
t is O to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl, with one or more substituents selected from hydroxy, methoxy, halogen, and amino; or R2 represents:
diphenylmethyl or(CH2)tAr; and j;) R1 and R2 taken together with the linking nitrogen represent;
N-tetrahydroquinolyl or N-tetrahydroisoquinolyl;
and the pharmaceutically acceptable salts thereof.
WO 94/25466 21~1~ 8 ~ -6- PCT/US94/04681~
Another sub group of compounds of the present invention are the compounds of formula (I) wherein:
n represents the integer 1 or 2; and i) R1 represents:
hydrogen, (C1 3) alkyl or amino (C1 3) alkyl; and R2 represents:
diphenylmethyl or(CH2)tAr;
1 0 wherein:
tis 1 to3and Ar represents phenyl, 2-furyl, 2-pyridyl, 4-pyridyl 2-N-methylpyrrolyl, 4-imidazolyl; or phenyl, 2-furyl, 2-pyridyl, 4-pyridyl, 2-N-methylpyrrolyl, 4-imidazolyl, with one to two substituents selected from hydroxy, methoxy, halogen, and amino; or ii) R1 and R2 taken together with the linking nitrogen represent N-tetrahydroisoquinolyl;
and the pharmaceutically acceptable salts thereof.
In one particular group of compounds of formula (I) Ar represents phenyl, furyl,pyridyl, N-methylpyrrolyl, imidazolyl or phenyl substituted with one or two 25 substituents independently selected from hydroxy, methoxy, halogen and amino.Typical Ar groups include phenyl and substituted phenyl, 2-furyl, 2-pyridyl, 4-pyridyl, 2-N-methylpyrrolyl and 4-imidazolyl. In one particular subgroup of compounds of formula (I), Ar is substituted phenyl or 4-pyridyl.
In another subgroup of compounds R1 represents hydrogen, lower alkyl, lower alkylaminolower alkyl or -(CH2)tAr, especially hydrogen or lower alkyl.
In another subgroup of compounds of formula (I), t is 1, 2, or 3, especially 1 and n is 1 or 2, especially 2.
Specific compounds of formula (I) are:
~0 94/2s466 PCT/US94/04681 -7- - r~
Example Number Compound Name 1. 7-(N-Ethyl-N-4-pyridylmethyl)- aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 2. 7-(4-Aminobenzyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 3. 7-(3-Methoxy-4-hydroxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 10 4. 7-Benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 5. 7-(N-Tetrahydroisoquinolino)methylene-10, 11-ethylenedioxy-20(S)-camptothecin, 6. 7-Dibenzylaminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 7. 7-(N-Methyl)benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 8. 7-Furylaminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 9. 7-(3-Phenylpropyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 10. 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 11. 7-(N-Ethyl, (2-chloro-6-fluorobenzyl))-aminomethylene-10, 11-ethylenedioxy- 20(S)-camptothecin, 12. 7-(3,4-Difluorobenzyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 13. 7-Diphenylmethylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 14. 7-((R) 1 -Phenylethyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 15. 7-((S) 1-Phenylethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 16. 7-(2(N-Methyl-2-pyrrol)-ethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 17. 7-(N-benzyl-N-(2-Dimethylaminoethyl)-aminomethylene-10, 11 -" ethylenedioxy-20(S)-camptothecin, 18. 7-(2-(4-lmidazolyl)ethyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 19. 7-(2-Pyridylmethyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, 20. 7-Benzylaminomethylene-10, 11-methylenedioxy-20(S)-camptothecin, and 216168~
21. 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11-methylenedioxy-20(S)-camptothecin, and pharmaceutically acceptable salts and solvates thereof.
Particular specific compounds of formula (I) are:
7-(N-Ethyl-N-4-pyridlymethyl)- aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(4-Aminobenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-1 0 camptothecin, 7-(3-Methoxy-4-hydroxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, and pharmaceutically acceptable salts and solvates thereof.
Prep~ration of Compounds According to one general process (A), compounds of formula (I) may be 20 prepared by the procedure shown in Step 2 of Scheme l:
~VO 94125466 2161 ~8 1 PCT/US94/04681 \N ~
(CH2)~0 ~ ~
( 11 ) / H 60 <
(V) ~
( ) / OH ~o SCHEME I
In Step 1 of Scheme 1, a compound of formula (Il), wherein X is a leaving group (as defined in J. March, Advanced Organic Chemistry, 3rd. Ed., page 179, 5 John Wiley & Sons, New York (1985)), for example, a halogen, e.g., chloro, may be reacted with a compound of formula (Ill) according to the method taught in US
Patent 4,894,456 (hereinafter, '456), issued January 16, 1990 to Wall et al., incor-porated herein by reference, to yield a compound of formula (IV).
The reaction of Step 1 is preferably carried out in the presence of an acid or base catalyst. The acid catalyst is preferably a strong mineral acid, for example hydrochloric, nitric, sulfuric and phosphoric or a strong organic acid such as C1-8 alkanoic acids and C1.12 arylsulfonic acids, especially p-toluenesulfonic acid. The base catalyst is preferably an inorganic base, for example sodium and potassium 1~ carbonate and sodium and potassium bicarbonate or an organic base such as a WO 94/25466 21~ 16 8 1 1o- PCT/US94/04681--sterically hindered base, for example, triethylamine and diisopropylamine.
This reaction may be carried out neat or in the presence of a polar or non-polar solvent. Preferred polar solvents are C1.6 alcohols, C1-6 ethers, and 5 dimethylformamide. Preferred non-polar solvents are branched or straight chained alkyl hydrocarbons having 4-10 carbon atoms and aromatic hydrocarbons having 6-20 carbon atoms especially toluene. The reaction is generally conducted with heating at reflux.
In Step 2, (General Process A) the compounds of formula (IV) may be converted to the compounds of formula (I) by displacement of the leaving group, X, with a compound of formula (V), wherein R1 and R2 are as defined for formula (I).
This displacement reaction may conveniently be carried out in a solvent system, for example water, a (C1 4) alkanol, a (C2 4) alkylene diol, 1-hydroxy-2-15 methoxyethane, dimethylacetamide (DMAC), N-methylpyrolidinone, dimethyl for-mamide (DMF), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), toluene, dioxane or a combination of these solvents in the presence of excess amine, i.e., excess compound of formula (V), with or without a base, e.g., potassium carbonate, and/or with Nal as a catalyst.
This method is particularly useful for preparing compounds of formula (I) wherein R1 is other than hydrogen.
Compounds of formula (V) are commercially available, taught in the chemical 25 literature, or may be readily prepared by one skilled in the art of organic chemistry using methods and materials known in the art of organic chemistry.
According to another general process (B), compounds of formula (I) may be prepared by the procedure shown in Step 2a of Scheme IA:
WO 94/2~i466 81 PCT/US94/04681 (CH2)~
b NH2 HNR1R2 ~ ( 11 ) ( V ) ~/Step 1a ~ o (IIA) (1ll) s~p 2a / OH ~b y ~-o OH
In Step 1a, a compounds of formula (Il) may be converted to a compounds of formula (IIA) by displacement of the leaving group, X (as defined for Scheme 1), with 5 a compound of formula (V), wherein R1 and R2 are as defined for formula (I). This displacement reaction may conveniently be carried out in a solvent system, for example, water, a (C14) alkanol, a (C2.4) alkylene diol, 1-hydroxy-2-meth-oxyethane, dimethylacetamide (DMAC), N-methylpyrolidinone, dimethyl formamide (DMF), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), toluene, dioxane or a 10 combination of these solvents (to the extent of miscibility) in the presence of excess amine, i.e., excess compound of formula (V), with or without a base, e.g., potassium carbonate, and/or with Nal as a catalyst.
In Step 2a (General Process B), compound of formula (IIA) is reacted with a 15 compound of formula (Ill) in a similar manner to that taught above in Scheme 1, Step 1, to yield a compound of formula (I).
WO 94/25466 2 1 6 1 6 8 1 -12- PCT/US94/0468~
Further alternate general method (C), particularly useful for preparing compounds of Formula (I) wherein R1 is hydrogen, is shown in Step 3b of Scheme x /~o (CH2)~NH2 D~ ~ (11) (Hal)3C~ NHR ~/ SteP lb C~ 2 I \N
\~NH~ OH~O
(llb) ~ (1ll) (Hal)30~0 ~NR2 H'B- / OH 6 Step 3b NR~ B-O C
(Ib) 2l~l68l ~VVO 94/25466 PCTfUS94tO4681 ln Step lb, a compound of formula (Va) (wherein "Hal" is halogen, i.e., fluoroj chloro, bromo or iodo) e.g., trifluoroacetamide, is reacted with a compound of for-mula (Il) in a polar, aprotic solvent, e.g., acetonitrile, in the presence of a base sol-uble in the polar, aprotic solvent, e.g., cesium carbonate if the solvent is acetonitrile, 5 to yield a compound of formula (llb).
In Step 2b, a compound of formula (llb) is reacted with a compound of formula (Ill) in a similar manner to that taught in Scheme 1, Step 1, to yield a compound of formula (IVb).
In Step 3b (General Process C), a compound of formula (IVb) is treated with an acid, H+B-, such as a mineral acid, e.g., hydrochloric acid, to yield a compound of formula (Ib), i.e. salt of a compound of formula (I). The compound of formula (Ib) may be treated with a base, such as an alkali metal hydroxide or carbonate, e.g., 15 sodium hydroxide or potassium carbonate, by standard method of the art to yield the corresponding free base. For example a compound of formula (Ib) may be stirred with an aqueous solution of potassium carbonate for about one to about four hours in the temperature range of from about 5 to about 100C. The free base can then be converted by conventional means to a pharmaceutically acceptable 20 salt if required.
The compounds of formula (Il) and (Ill) may be prepared according to the procedure described in EP0 540 099 A1.
The novel, intermediate compounds of formulas (lla), (llb) and (IVb) are within the scope of this invention.
A compound of formula (I) according to the invention may be converted into another compound of the invention using conventional procedures.
Thus, for example, a compound of formula (I) wherein R1 represents a hydrogen atom, may be alkylated using conventional techniques. The reaction may be effected using a suitable aklylating agent such as an alkyl halide, an alkyl tosylate or a dialkylsulphate. The alkylation reaction may conveniently be carried out in an organic solvent such as an amide, e.g. dimethylformamide, or an ether,e.g. tetrahydrofuran, preferably in the presence of a base. Suitable bases include, for example, alkali metal hydrides, such as sodium hydride, alkali metal carbonates, such as sodium carbonate, or potassium methoxide, ethoxide or t-butoxide. The alkylation reaction is conveniently carried out at a temperature of 21616~1 from about 25 to about 1 00C.
Alternately, a compound of formula (I) wherein R1 represents a hydrogen atom may be converted to another compound of formula (I) by reductive alkylation.
5 Reductive alkylation with an appropriate aldehyde or ketone may be effected using an alkaline earth metal borohydride or cyanoborohydride. The reaction medium, co~veniently in an alcohol, e.g. methanol or ethanol or an ether, e.g. dioxan ortetrahydrofuran, optionally in the presence of water. The reaction may conveniently be carried out at a temperature in the range of 0 to 100C, preferably about 5 to 10 about 50C.
Alternatively, a compound of formula (I) wherein R1 represents a lower alkenyl group may be converted to another compound of formula (I) wherein Rl represents a lower alkyl group. Reduction may conveniently be effected in the presence of 15 hydrogen and a metal catalyst, for example, Raney nickel or a nobel metal catalyst such as palladium, platinum, platinum oxide or rhodium, which may be supported, for example, on charcoal. The reaction may be effected in a solvent such as an alcohol, for example ethanol and conveniently at a temperature of from about -10 to about +50C, preferably about 20 to about 30C.
A compound of formula (I) according to the invention, or a salt thereof may br prepared by subjecting a protected derivative of formula (I) or a salt thereof to reac-tion to remove the protecting group or groups.
Thus, at an earlier stage in the preparation of a compound of formula (I) or a salt thereof it may have been necessary and/or desirable to protect one or more sensitive groups in the molecule to prevent undesirable side reactions.
The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See for example, "Protective Groups in Organic Chemistry~ Ed. J.F.W. McOmie (Plenum Press 1973) or "Protective Groups in Organic Synthesis" by Theodora W. Greene (John Wiley and Sons 1981).
Conventional amino protecting groups may include, for example, aralkyl 3~ groups, such as benzyl, diphenylmethyl or triphenylmethyl groups; and acyl groups such as N-benzyloxycarbonyl or t-butoxycarbonyl. Thus, compounds of general formula (I) wherein R1 represents hydrogen may be prepared by deprotection of a corresponding protected compound.
~vo 94/25466 -15- ~681 PcT/uss4/046s1 Hydroxy groups may be protected, for exampie, by aralkyl groups, such as benzyl, diphenylmethyl or triphenylmethyl groups, acyl groups, such as acetyl, sili-con protecting groups, such as trimethylsilyl or t-butyl dimethylsilyl groups or as tetrahydropyran derivatives.
Removal of any protecting groups present may be achieved by conventional procedures. Thus, an aralkyl groups such as benzyl, may be cleaved by hy-drogenolysis in the presence of a catalyst (e.g. palladium on charcoal); an acylgroup such as N-benzyloxycarbonyl may be removed by hydrolysis with, for ex-ample, hydrogen bromide in acetic acid or by reduction, for example by catalytichydrogenation; silicon protecting groups may be removed, for example, by treat-ment with fluoride ion or by hydrolysis under acidic conditions; tetrahydropyrangroups may be cleaved by hydrolysis under acidic conditions.
As will be appreciated, in any of the processes described above, it may be necessary or desired to protect any sensitive groups in the molecule as just de-scribed. Thus, a reaction step involving deprotection of a protected derivative of general formula (I) or a salt thereof may be carried out subsequent to any of the above described processes.
Thus, according to a further aspect of the invention, the following reactions may, if necessary and/or desired by carried out in any appropriate sequence sub-sequent to any of the processes (i) removal of any protecting groups; and (ii) conversion of a compound of formula (I) or a salt thereof into a pharmaceutically acceptable salt thereof.
Where it is desired to isolate a compound of the invention as a salt, for exam-ple, as an acid addition salt, this may be achieved by treating the free base of gen-eral formula (I) with any appropriate acid, preferably with an equivalent amount, or with creatinine sulphate in a suitable solvent (e.g. aqueous ethanol).
As well as being employed as the last main step in the preparative sequence, the general methods indicated above for the preparation of the compounds of the invention may also be used of the introduction of the desired groups at an inter-mediate stage in the preparation of the required compound. It should therefore be appreciated that in such multi-stage processes, the sequence of reactions shouldbe chosen in order that the reacting conditions do not affect groups present in the WO 94/25466 2 ~ 6 1 6 81 PCT/US94/04681~
molecule which are desired in the final product.
The biological activity of the compounds of formula (I) appears to reside in theS enantiomer, and the R enantiomer has little or no activity. Thus, the S enan-5 tiomer of a compound of formula (I) is generally preferred over a mixture of R and Ssuch as the racemic mixture. However, if the R enantiomer were desired, e.g., for control studies or synthesis of other compounds, it could be conveniently prepared by the procedure above using the R enantiomer of the compound of formula (Ill) prepared according to the teachings of '512.
A compound of formula (I) prepared by reaction Scheme I or Scheme IA may be purified by conventional methods of the art, e.g., chromatography, distillation or crystallization.
15 Cle~vable Complex 7n vitro Assay The data in Table A, below, shows the relative topoisomerase Type I inhibitory activity of the compounds of Formula (I). This assay performed according to the method described in Hsiang, Y. et al., J. Blol. Chem., 260:14873-14878 (1985), 20 correlates well with in vivo anti-tumor activity of topoisomerase inhibitors in animal models of cancer, e.g., camptothecin and its analogs. See Hsiang et al., Cancer Research, 49:4385-4389 (1989) and Jaxel et al., Cancer Research, 49:146~-1469 (1989).
Those compounds which exhibit observable activity at concentrations greater 25 than 2000 nM ("+~ in Table A) are considered weakly to moderately active, while those with activity at concentrations less than 500 nM (U++++~ in Table A) are very active. The term ~ICsoU means the concentration of a compound of formula (I) at which 50% of the DNA substrate has been captured by topoisomerase 1.
TABLE A
Topoisomerase Inhibitory Activity of Compounds of Formula (I) in the Cleavable Complex Assay Example Isomeric Relative Number form 4 (S) 1 l l l 8 (S) ++++
(S) m 11 14 (S) ~+++
(S) ++++
~0 94/2~466 -17- ~1 PCT/US94/04681 16 (S) ++++
21 (S) ++++
2 (S) ++++
19 (S) ++++
3 (S) ++++
(S) +It I
18 (S) ++++
6 (S) +++
7 (S) +++
(S) +++
12 (S) +++
17 (S) +++
(S) ++
11 (S) ++
13 (S) ++
9 (S) ++
ICso Range Symbol nM
++++ <~500 +++ <~ 1000~~500 ++ <~2000>~ 1000 + >~2000 Utility In view of such activity, the compounds of formula (I) are active against a widespectrum of mammalian (including human) tumors and cancerous growths such as cancers of the oral cavity and pharynx (lip, tongue, mouth, pharynx), esophagus,stomach, small intestine, large intestine, rectum, liver and biliary passages, pan-30 creas, larynx, lung, bone, connective tissue, skin, colon, breast, cervix uteri, corpusendometrium, ovary, prostate, testis, bladder, kidney and other urinary tissues, eye, brain and central nervous system, thyroid and other endocrine gland, leukemias (Iymphocytic, granulocytic, monocytic), Hodgkin's disease, non-Hodgkin's Iym-phomas, multiple myeloma, etc. Hereir~ the terms utumor", Ucancer" and "cancerous 35 growthsU are used synonymously.
The amount of compound of formula (I) required to be effective as an antitu-mor agent will, of course, vary with the individual mammal being treated and is ul-timately at the discretion of the medical or veterinary practitioner. The factors to be 2~ 6~ .
W094/25~6 PCT~S94/0~81 . -18-considered include the condition being treated, the route of administration, the na-ture of the formulation, the mammal's body weight, surface area, age and generalcondition, and the particular compound to be administered. However, a suitable effective antitumor dose is in the range of about 0.1 to about 200 mg/kg body 5 weight per day, preferably in the range of about 1 to about 100 mg/kg per day. The total daily dose may be given as a single dose, multiple doses, e.g., two to six times per day, or by intravenous infusion for a selected duration. Dosages above or be-low the range cited above are within the scope of the present invention and may be administered to the individual patient if desired and necessary.
For example, for a 75 kg mammal, a dose range would be about 75 to about 7500 mg per day, and a typical dose would be about 800 mg per day. If discrete multiple doses are indic~te~, treatment might typically be 200 mg of a compound of formula (I) given 4 times per day.
Formul~tions Formulations of the present invention, for medical use, comprise an active compound, i.e., a compound of formula (I), together with an acceptable carrier therefof and optionally other therapeutically active ingredients. The carrier must be pharmaceutically acceptable in the sense of being compatible with the other in-gredients of the formulation and not deleterious to the recipient therefor.
The present invention, therefore, further provides a pharmaceutical formula-tion comprising a compound of formula (I) together with a pharmaceutically accept-able carrier thereof.
The formulations include those suitable for oral, rectal or parenteral (including subcutaneous, intramuscular and intravenous) administration. Preferred are those suitable for oral or parenteral administration.
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methodsinclude the step of bringing the active compound into association with a carrierwhich constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into asso-ciation with a liquid carrier or a finely divided solid carrier and then, if necessary, shaping the product into desired unit dosage form.
~WO 94/25466 6~7~81 PCT/US94/04681 Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, eachcontaining a predetermined amount of the active compound; as a powder or gran-ules; or a suspension or solution in an aqueous liquid or non-aqueous liquid, e.g., 6 a syrup, an elixir, an emulsion or a draught.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form, e.g., a powder or 10 granules, optionally mixed with accessory ingredients, e.g., binders, lubricants, in-ert diluents, surface active or dispersing agents. Molded tablets may be made bymolding in a suitable machine, a mixture of the powdered active compound with any suitable carrier.
A syrup or suspension may be made by adding the active compound to a concentrated, aqueous solution of a sugar, e.g., sucrose, to which may also be added any accessory ingredients. Such accessory ingredient(s) may include flavor-ing, an agent to retard crystallization of the sugar or an agent to increase the solu-bility of any other ingredient, e.g., as a polyhydric alcohol, for example, glycerol or 20 sorbitol.
Formulations for rectal or vaginal administration may be presented as a sup-pository with a conventional carrier, e.g., cocoa butter or Witepsol S55 (trademark of Dynamite Nobel Chemical, Germany, for a suppository base).
For transdermal administration, the compounds according to the invention may be formulated as creams, gels, ointments or lotions or as a transdermal patch.
Such compositions may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening, gelling, emulsifying, stabilizing, dispersing, 30 suspending and/or coloring agents.
Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the recipient. Such formulations suitably comprise a solution or 35 suspension of a pharmaceutically and pharmacologically acceptable acid addition salt of a compound of the formula (I) that is isotonic with the blood of the recipient.
Thus, such formulations may conveniently contain distilled water, 5% dextrose indistilled water or saline and a pharmaceutically and pharmacologically acceptable acid addition salt of a compound of the formula (I) that has an appropriate solubility WO 94/2~466 2~ 681 -20- PCTIUS94/04681~
in these solvents, for example the hydrochloride. Useful formulations also com-prise concentrated solutions or solids containing the compound of formula (I) which upon dilution with an appropriate solvent give a solution suitable for parental ad-ministration above.
In addition to the aforementioned ingredients, the formulations of this inven-tion may further include one or more optional accessory ingredient(s) utilized in the art of pharmaceutical formulations, e.g., diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, suspending agents, preservatives 10 (including antioxidants) and the like.
EXAM PLES
The following examples illustrate aspects of this invention but should not be 15 construed as limitations. The symbols and conventions used in these examples are consistent with those used in the contemporary chemical literature, for example, the Journal of the American Chemical Society. As used here in the term "room temperature" means about 25C.
GENERAL PRO~:EDURE
A flask is charged with (S)-7-chloromethyl-10,11-ethylenedioxycamptothecin (25-150 mg, 0.06-0.33 mmol), catalytic sodium iodide (1-15 mg, 99.99% Aldrich), and anhydrous 1,4-dioxane (2-50 mL). The amine is added (2-5 equiv. neat), and 25 the stirred slurry was heated in an oil bath at 75-95 C. The reaction was moni-tored for disappearance of starting material by thin layer chromatography. The mixture is worked up by removing the solvent with a rotary evaporator, and triturat-ing the residue with ether. The solid that is collected by suction filtration is purified by silica gel chromatography or reverse phase HPLC (Rainin Dynamax 60A col-30 umn, eluting with 2% trifluoroacetic acid in water (70-80%) and 4:1 acetonitrile THF
(20-30%), monitoring at 254 nm) to afford the product amine as either the free base or the trifluoroacetic acid salt respectively.
WO 94/25466 `, 61~i681 PCT/US94/04681 F~ample 1 7-(N-Fthyl-N-4-pyridylmethyl)- ~minomethylene-10. 11 -ethylenedioxy-20(S)-cam~ ptothecin (Compound 1) (A) 6'-amino-3',4'-ethylenedioxy-2-chloroacetophenone A 1-L, three-necked, round-bottomed flask was fitted with a magnetic stirring bar, thermometer, reflux condenser with calcium chloride filled drying tube, and a nitrogen inlet. The reaction vessel was charged with dry methylene chloride (10010 ml) and 1,4-benzodioxane-6-amine (15.12 9, 100 mmol). The reaction vessel wascooled to 0 C followed by slow addition of 400 ml of a lM solution of boron trichloride in methylene chloride while maintaining an internal temperature at or below 10C. Aluminum chloride (13.34 9, 100 mmol) was added quickly in three portions followed by addition of chloroacetonitrile (7 ml, 110 mmol). The reaction 15 was stirred for 30 min at 0 C then heated to 40C for 16 hours. The reaction was removed from heat, allowed to cool to room temperature, then quenched into a mixture of 1 kg of ice/ 500 ml of lN HCI. The mixture was stirred until no solids were observed. The methylene chloride layer was removed and the aqueous layer was extracted twice with methylene chloride. The organic layers were combined, 20 washed with brine, dried over magnesium sulfate, filtered, treated with decolorizing carbon, filtered through a pad of celite, and concentrated to a solid residue. The solid was recrystallized from ethyl acetate/hexanes to give 8.3 g (36.5%) of 6'-amino-3',4'-ethylenedioxy-2-chloroacetophenone.
MS (Cl): m/z 228 (M+H+).
1 H NMR (CDCI3):â 7.14 (s, lH), 6.15 (s, 1 H), 4.57 (s, 2H), 4.3 (m, 2H), 4.2 (m, 2H), 1.6 (s, broad, 2H).
Anal. (CloHloclNo3) calc. found C 52.76 52.66 H 4.43 4.53 7-Chloromethyl-10,11-ethylenedioxy-20(S)-camptothecin. Into a 250 ml round-30 bottomed flask equipped with a stirring bar, a reflux condeser and a Dean Stark WO 94/2~466 2 I 6 1 ~ 8 1 PCT/US94/04681--trap were added 1.82 9 (8.0 mmol) of 2'-amino-4',5'-ethylenedioxy-2-chloroacetophenone, 40 ml dry toluene and 2.0 g (7.6 mmol) of (S) tricyclic keto-lactone. The reaction was stirred under nitrogen and refluxed for 0.5 hours. Thereaction was allowed to cool followed by addition of 100 mg, (0.~3 mmol) of p-5 toluenesulfonic acid. The reaction was then heated to reflux for 36 hours. Thereaction was cooled, and the solids were collected by filtration and washed withtoluene followed by thorough washings of the solids by anhydrous ethanol. The remaining greenish-brown solid was dried under vacum at room temperature yielding 2.67 9 (77.2%) of > than 97% pure materal.
1H NMR (DMSO-d6): ~ 7.47 (s,1H), 7.32 (s, 1H), 6.98 (s, 1H), 5.15 (s, 1H), 5.06 (s, 1H), 4.97 (s, 1H), 4.19 (s, 4H), 2.23 (s, 2H), 1.6 (m, 2H), 0.68 (m, 3H).
MS M+H = 455.
HRMS: Calc. 455.1009; Found 455.1000.
Anal. (C23H1gN2ClO6) C, H
calc. found C 60.73 60.70 H 4.21 4.30 (C) 7-(N-Ethyl-N-4-pyridylmethyl)- aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin A flask is charged with (S)-7-chloromethyl-10,11 -ethylenedioxycamptothecin (0.60 g,1.3 mmol), catalytic sodium iodide (20 mg, 99.99% Aldrich), and anhydrous 20 1,4-dioxane (120 mL). The 4-(ethylaminomethyl)pyridine (0.54 g, 4.0 mmol) is added and the stirred slurry was heated in an oil bath at 75-95 C. The reactionwas monitored for disappearance of starting material by thin layer chromatography.
The mixture is worked up by removing the solvent with a rotary evaporator, and triturating the residue with ether. The solid that is collected by suction filtration is 25 purified by reverse phase HPLC (Rainin Dynamax 60A column, eluting with 2%
trifluoro~cetic acid in water (70-80%) and 4:1 acetonitrile:THF (20-30%), monitoring at 254 nm) to afford the product amine as the trifluoroacetic acid salt.
Mp 178-180C.
W094125466 ~ 681 PCl/US94/04681 FAB MS MH+ 555.
1H NMR (d6-DMSO) ~ 8.58(d, 2H), 7.83(s, lH), 7.58(d, 2H), 7.52(s, 1H), 7.24(s, 1H), 5.42(s, 2H), 5.31(s, 2H), 4.46(s, 4H), 4.15(br s, 2H), 3.79(br s, 2H), 2.65(m, 2H), 1.86(m, 2H), 1.16(t, 3H), 0.87(t, 3H).
FxamDle 2 7-(4-aminobenzyl)aminomethyl-10.11 -ethylenedioxy-(20S)-camptothecin (ComDound ~) A flask is charged with 7-chloromethyl-10,11-ethylenedioxy-(20S)-camptothecin (252 mg, 0.555 mmol), Nal (42 mg, 0.307 mmol) and anhydrous 1,4-dioxane (2-50 mL). 4-Aminobenzylamine (192 mL, 207 mg, 1.7 mmol), is added and the stirred slurry is heated in an oil bath at 75-95 C. The reaction is monitored for disappearance of starting material by thin layer chromatography. The mixture is 15 worked up by removing the solvent with a rotary evaporator, and triturating the residue with ether. The crude product is collected by suction filtration and purified by flash chromatography (eluting with 6:5:1 EtOAc/CHCI3/MeOH) to afford the amine product which was further purified by recrystallizing from t-butylmethyl ether to afford 100.6 mg (34% yield) of pure product. The TLC salt was formed by 20 dissolving in 2% aqueous trifluoroacetic acid and Iyophylizing to afford the product TFA salt (141.4 mg) as a bright yellow solid, mp 280 C (dec).
1H NMR (300 MHz, DMSO-d6): ~ 0.85 (t, 3H, J=7.1), 1.78-1.95 (m, 2H), 4.27 (bs, 1H), 4.45 (s, 2H), 4.65 (bs, 1H), 5.42 (s, 2H), 6.63 (d, 1H, J=8.30), 7.21 (d, 1H, J=8.30), 7.27 (s, 1 H), 7.63 (s, 1 H), 7.75 (s,1 H), 9.05 (bs, 2H).
25 Low resolution ms (M+1): 541.3 (calcd 541).
Anal. Calcd C30H2gN4O8-2TFA-2.5H2O:
calc. found C 48.23 48.25 H 4.22 4.18 N 6.43 6.39.
wo 94/2~466 ' -24- PCT/US94/04681 Fxample 3 7-(3-Methoxy-4-hydroxyben7yl)-aminomethylene-10. 11-ethylenedioxy-~O(S)-5 ~rnptothecin (Compound 3) A flask is charged with (S)-7-chloromethyl-10,11-ethylenedioxycamptothecin ( 250mg, 0. 549 mmol), catalytic sodium iodide ( 20 mg, 99.99% Aldrich), and anhydrous 1,4-dioxane (25 mL). 4-Hydroxy-3-methoxybenzylamine is added ( 254 mg,1.66 mmol neat), and the stirred slurry was heated in an oil bath at 75-95 C for 18h.
10 The reaction was monitored for disappearance of starting material by thin layer chromatography. The mixture is worked up by removing the solvent with a rotary evaporator, and triturating the residue with ether. The solid that is collected by suction filtration is purified by reverse phase HPLC (Rainin Dynamax 60A column,eluting with 2% trifluoroacetic acid in water (70-80%) and 4:1 acetonitrile THF (20-15 30%), monitoring at 254 nm) to afford the product amine as the trifluoroacetic acidsalt 214 mg (68%).
MS (FAB ) (M+H) +572.3.
1H NMR (DMSO-d6): o 7.74 (s,1H), 7.63 (s,1H), 7.28 (s,1H), 7.24 (br s,1H), 6.95 (d,1H,j=8Hz), 6.82 (d,1H,j=8Hz), 5.42 (s,2H), 4.68 (br s,1H), 4.46 (br s,2H), 4.35 (br 20 s,1H), 3.78 (s,3H), 1.86 (m,2H), 0.85 (t,2H).
Fxamples 4-~1 The following compounds of formula (I) are prepared by the procedure taught 25 in Scheme 1, in an analogous manner to Example 1 using the appropriate intermediate compounds of formulas (Il), (Ill), and (V).
4. 7-Benzylaminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, (as the trifluoroacetic acid (TFA) salt) 30 Nominal mass spectrum: MH+526, mp = >300C (decomposition).
5. 7-(N-tetrahydroisoquinolino)methylene- 10, 11 -ethylenedioxy-20(S)-camptothecin, (as TFA salt) 35 Nominal mass spectrum: MH+552, mp = 265-270C.
WO 94/25466 6'~1 PCT/US94/04681 6. 7-Dibenzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+630, mp = 180C (decomposition).
7. 7-(N-Methyl)benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+540, mp = 205C (decomposition).
8. 7-Furylaminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, (as TFA
salt) Nominal mass spectrum: MH+516, mp = 185C (decomposition).
salt) Nominal mass spectrum: MH+516, mp = 185C (decomposition).
9. 7-(3-Phenylpropyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+554, mp = 280C (decomposition).
10. 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+586, mp = 190C.
11. 7-(N-Ethyl, (2-chloro-6-fluorobenzyl))-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+606, mp = 172C (decomposition).
12. 7-(3,4-Difluorobenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+562, mp = 274-277C.
13. 7-Diphenylmethylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+602, mp = 250C (decomposition).
:2~6i~8~
:2~6i~8~
14. 7-((R) 1-Phenylethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+540, 5 mp = 265-270C.
15. 7-((S) 1 -Phenylethyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+552, 10 mp = 265-270C.
16. 7-(2(N-Methyl-2-pyrrol)-ethyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+552, 15 mp = 160C (decomposition).
17. 7-(N-benzyl-N-(2-Diethylaminoethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+597, mp = 170-173C.
18. 7-(2-(4-lmidazolyl)ethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+530, mp = 190C.
19. 7-(2-Pyridylmethyl)-aminomethylene-10, 11 -ethylenedioxy-20(S)-camptothecin, (as TFA salt) Nominal mass spectrum: MH+527, 30 mp = >300C.
20. 7-Benzylaminomethylene-10, 11-methylenedioxy-20(S)-camptothecin, (as the hydrochloride salt Nominal mass spectrum: MH+512, 35 mp = >256C (decomposition).
~N0 94/25466 i 2~
~N0 94/25466 i 2~
21. 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11-methylenedioxy-20(S)-camptothecin, (as the hydrochloride salt) Nominal mass spectrum: MH+472, mp = 225C (decomposition).
Fxample 2 Ph~rmaceutic~l formulations (A) Transdermal System In~redients Amount Active compound 600.0 mg Silicone fluid 450.0 mg Colloidal silicone dioxide 25.0 mg 15 The silicone fluid and active compound, i.e., a compound of formula (I), are mixed together and the colloidal silicone dioxide is reacted with to increase viscosity. The material is then dosed into a subsequently heat sealed polymeric laminate comprised of the following: polyester release liner, skin contact adhesive composed of silicone or acrylic polymers, a control membrane which is a polyolefin 20 (e.g. polyethylene),polyvinyl acetate or polyurethane, and an impermeable backing membrane made of a polyester multilaminate. The system described is a 10 sq. cm patch.
(B) Oral Tablet In~redients Amount Active compound 200.0 mg Starch 20.0 mg Magnesium Stearate 1.0 mg The active compound and the starch are granulated with water and dried.
30 Magnesium stearate is added to the dried granules and the mixture is thoroughly blended. The blended mixture is compressed into a tablet.
(C) Suppository In~redients Amount Active compound 150.0 mg Theobromine sodium salicylate 250.0 mg Witepsol S55 1725.0 mg The inactive ingredients are mixed and melted. The active compound is then 2 ~
distributed in the molten mixture, poured into molds and allowed to cool.
(D) Injection In~redients Amount Active Compound 20.0 mg Buffering Agents q.s.
Propylene glycol 0.4 Water for injection 0.6 mL
10 The active compound and buffering agents are dissolved in the propylene glycol at about 50C. The water for injection is then added with stirring and the resulting solution is filtered, filled into an ampule, sealed and sterilized by autoclaving.
(E) Capsule In~redients Amount Active Compound 200.0 mg Lactose 450.0 mg Magnesium stearate 5.0 mg 20 The finely ground active compound is mixed with the lactose and stearate and packed into a gelatin capsule.
Fxample 2 Ph~rmaceutic~l formulations (A) Transdermal System In~redients Amount Active compound 600.0 mg Silicone fluid 450.0 mg Colloidal silicone dioxide 25.0 mg 15 The silicone fluid and active compound, i.e., a compound of formula (I), are mixed together and the colloidal silicone dioxide is reacted with to increase viscosity. The material is then dosed into a subsequently heat sealed polymeric laminate comprised of the following: polyester release liner, skin contact adhesive composed of silicone or acrylic polymers, a control membrane which is a polyolefin 20 (e.g. polyethylene),polyvinyl acetate or polyurethane, and an impermeable backing membrane made of a polyester multilaminate. The system described is a 10 sq. cm patch.
(B) Oral Tablet In~redients Amount Active compound 200.0 mg Starch 20.0 mg Magnesium Stearate 1.0 mg The active compound and the starch are granulated with water and dried.
30 Magnesium stearate is added to the dried granules and the mixture is thoroughly blended. The blended mixture is compressed into a tablet.
(C) Suppository In~redients Amount Active compound 150.0 mg Theobromine sodium salicylate 250.0 mg Witepsol S55 1725.0 mg The inactive ingredients are mixed and melted. The active compound is then 2 ~
distributed in the molten mixture, poured into molds and allowed to cool.
(D) Injection In~redients Amount Active Compound 20.0 mg Buffering Agents q.s.
Propylene glycol 0.4 Water for injection 0.6 mL
10 The active compound and buffering agents are dissolved in the propylene glycol at about 50C. The water for injection is then added with stirring and the resulting solution is filtered, filled into an ampule, sealed and sterilized by autoclaving.
(E) Capsule In~redients Amount Active Compound 200.0 mg Lactose 450.0 mg Magnesium stearate 5.0 mg 20 The finely ground active compound is mixed with the lactose and stearate and packed into a gelatin capsule.
Claims (26)
1. A compound of formula (1), (I) wherein n represents the integer 1 or 2; and i) R1 represents:
hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkylamino lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr wherein:
t is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, or imidazolyl with one or more substituents independently selected from hydroxy, methoxy, halogen, and amino;
and R2 represents:
diphenylmethyl or(CH2)tAr; or ii) R1 and R2 taken together with the linking nitrogen represent;
N-tetrahydroquinolyl or N-tetrahydroisoquinolyl;
or a pharmaceutically acceptable salt or solvate thereof.
hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkylamino lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr wherein:
t is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, or imidazolyl with one or more substituents independently selected from hydroxy, methoxy, halogen, and amino;
and R2 represents:
diphenylmethyl or(CH2)tAr; or ii) R1 and R2 taken together with the linking nitrogen represent;
N-tetrahydroquinolyl or N-tetrahydroisoquinolyl;
or a pharmaceutically acceptable salt or solvate thereof.
2. A compound according to Claim 1 wherein Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl or phenyl substituted with one or two substituents independently selected from hydroxy, methoxy, halogen and amino.
3. A compound according to Claim 1 or Claim 2 wherein Ar represents phenyl or substituted phenyl, 2-furyl, 2-pyridyl, 4-pyridyl, 2-N-methylpyrrolyl or 4-imidazolyl.
4. A compound according to any one of Claims 1 to 3 wherein Ar represents substituted phenyl or 4-pyridyl.
5. A compound according to any one of Claims 1 to 4 wherein R1 represents hydrogen, lower alkyl, lower alkylamino lower alkyl or -(CH2)tAr.
6. A compound according to any one of Claims 1 to 5 wherein R1 represents hydrogen or lower alkyl.
7. A compound according to any one of Claims 1 to 6 wherein t is 1, 2 or 3.
8. A compound according to any one of Claims 1 to 7 wherein t is 1.
9. A compound according to any one of Claims 1 to 8 wherein n is 1 or 2.
10. A compound according to any one of Claims 1 to 9 wherein n is 1.
11. The compound which is:
7-(N-Ethyl-4-pyridylmethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin;
7-(4-Aminobenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin; or 7-(3-Methoxy-4-hydroxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin;
or a pharmaceutically acceptable salt or solvate thereof.
7-(N-Ethyl-4-pyridylmethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin;
7-(4-Aminobenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin; or 7-(3-Methoxy-4-hydroxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin;
or a pharmaceutically acceptable salt or solvate thereof.
12. A compound according to Claim 1 wherein n represents the integer 1 or 2; andi) R1 represents hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr wherein t is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl or imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl or imidazolyl with one or more substituents selected from hydroxy, methoxy, halogen and amino; and R2 represents diphenylmethyl or (CH2)tAr; or ii) R1 and R2 taken together with the linking nitrogen represent N-tetrahydroquinolyl or N-tetrahydroisoquinolyl.
13. A compound according to Claim 1 wherein n represents the integer 1 or 2; and i) R1 represents hydrogen, (C1-3) alkyl or amino (C1-3) alkyl; and R2 represents diphenylmethyl or (CH2)tAr wherein t is 1 to 3 and Ar represents phenyl, 2-furyl, 2-pyridyl, 4-pyridyl, 2-N-methylpyrrolyl, 4-imidazolyl; or phenyl, 2-furyl, 2-pyridyl, 4-pyridyl, 2-N-methylpyrrolyl or 4-imidazolyl with one to two substituents selected from hydroxy, methoxy, halogen and amino; or ii) R1 and R2 taken together with the linking nitrogen represent N-tetrahydroisoquinolyl.
14. A compound according to any one of Claims 1 to 13 in the R configuration.
15. A compound according to any one of Claims 1 to 13 in the S configuration.
16. A compound according to any one of Claims 1 to 14 for use in therapy.
17. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 14 or pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier.
18. A method of inhibiting topoisomerase I enzyme comprising contacting said enzyme with an effective topoisomerase I inhibitory amount of a compound according to any one of Claims 1 to 14.
19. A method of treating a tumor in a mammal comprising administering to said mammal an antitumor effective amount of a compound according to any one of Claims 1 to 14.
20. The use of a compound according to any one of Claims 1 to 14 in the preparation of a medicament for use in the treatment of tumors.
21. The compound of Claim 1 which is:
7-(N-Ethyl-N-4-pyridylomethyl)- aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(4-Aminobenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(3-Methoxy-4-hydroxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(N-Tetrahydroisoquinolino)methylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Dibenzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(N-Methyl)benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Furylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(3-Phenylpropyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(N-Ethyl, (2-chloro-6-fluorobenzyl))-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(3,4-Difluorobenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Diphenylmethylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-((R) 1-Phenylethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-((S) 1-Phenylethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(2(N-Methyl-2-pyrrol)-ethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(N-benzyl-N-(2-Dimethylaminoethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(2-(4-lmidazolyl)ethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(2-Pyridylmethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Benzylaminomethylene-10, 11-methylenedioxy-20(S)-camptothecin, or 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11-methylenedioxy-20(S)-camptothecin.
7-(N-Ethyl-N-4-pyridylomethyl)- aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(4-Aminobenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(3-Methoxy-4-hydroxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(N-Tetrahydroisoquinolino)methylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Dibenzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(N-Methyl)benzylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Furylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(3-Phenylpropyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(N-Ethyl, (2-chloro-6-fluorobenzyl))-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(3,4-Difluorobenzyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Diphenylmethylaminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-((R) 1-Phenylethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-((S) 1-Phenylethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(2(N-Methyl-2-pyrrol)-ethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(N-benzyl-N-(2-Dimethylaminoethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(2-(4-lmidazolyl)ethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-(2-Pyridylmethyl)-aminomethylene-10, 11-ethylenedioxy-20(S)-camptothecin, 7-Benzylaminomethylene-10, 11-methylenedioxy-20(S)-camptothecin, or 7-(3,4-Dimethoxybenzyl)-aminomethylene-10, 11-methylenedioxy-20(S)-camptothecin.
22. A process for preparing a compound of formula (I) as defined in Claim 1 or apharmaceutically acceptable salt or solvate thereof which comprises:
(A) reacting a compound of formula (IV) (IV) wherein X is a leaving group, witn a compound of formula (V) HNR1R2 (V) wherein R1 and R2 are as defined for formula (I); or (B) reacting a compound of the formula (IIA) (IIA) wherein R1 and R2 are as defined for formula (I), with a compound of formula (III) (III) or (C) for the preparation of compounds of formula (I) wherein R1 is hydrogen, reacting a compound of formula (IVb) (IVb) wherein Hal is halogen and R2 is as defined for formula (I), with an acid to yield a salt of a compound of formula (I); and if necessary and/or desired subjecting the compound thus obtained to one or more further reactions comprising:
i) converting the resulting compound of formula (I) or a salt or a solvate or a protected derivative thereof into another compound of formula (I) and/or ii) removing any protecting group or groups and/or iii) converting a compound of formula (I) or a salt or solvate thereof into a physiologically acceptable salt or solvate thereof.
(A) reacting a compound of formula (IV) (IV) wherein X is a leaving group, witn a compound of formula (V) HNR1R2 (V) wherein R1 and R2 are as defined for formula (I); or (B) reacting a compound of the formula (IIA) (IIA) wherein R1 and R2 are as defined for formula (I), with a compound of formula (III) (III) or (C) for the preparation of compounds of formula (I) wherein R1 is hydrogen, reacting a compound of formula (IVb) (IVb) wherein Hal is halogen and R2 is as defined for formula (I), with an acid to yield a salt of a compound of formula (I); and if necessary and/or desired subjecting the compound thus obtained to one or more further reactions comprising:
i) converting the resulting compound of formula (I) or a salt or a solvate or a protected derivative thereof into another compound of formula (I) and/or ii) removing any protecting group or groups and/or iii) converting a compound of formula (I) or a salt or solvate thereof into a physiologically acceptable salt or solvate thereof.
23. A compound of Claim 1 wherein the E ring is open.
24. A compound of the formula (IIA):
(IIA) wherein n represents the integer 1 or 2; and (i) R1 represents hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkylamino lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr wherein: t is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl with one or more substituents independently selected from hydroxy, methoxy, halogen and amino; and R2 represents diphenylmethyl or (CH2)tAr; or (ii) R1 and R2 taken together with the linking nitrogen represent N-tetrahydroquinolyl or N-tetrahydroisoquinolyl;
or a salt or solvate thereof.
(IIA) wherein n represents the integer 1 or 2; and (i) R1 represents hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkylamino lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr wherein: t is 0 to 5 and Ar represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl with one or more substituents independently selected from hydroxy, methoxy, halogen and amino; and R2 represents diphenylmethyl or (CH2)tAr; or (ii) R1 and R2 taken together with the linking nitrogen represent N-tetrahydroquinolyl or N-tetrahydroisoquinolyl;
or a salt or solvate thereof.
25. A compound of formula (IIb) (IIb) wherein n represents the integer 1 or 2, Hal is halogen and R1 represents hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, lower alkylamino lower alkyl, amino lower alkyl, lower alkoxy lower alkyl or (CH2)tAr wherein: t is 0 to 5 andAr represents phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl, with one or more substituents independently selected from hydroxy, methoxy, halogen and amino, or a salt or solvate thereof.
26. A compound of formula (IVb) (IVb) wherein n represents the integer 1 or 2, Hal is halogen and R2 is diphenylmethyl or (CH2)tAr wherein: t is 0 to 5 and Ar represents phenyl, furyl,pyridyl, N-methylpyrrolyl, imidazolyl; or phenyl, furyl, pyridyl, N-methylpyrrolyl, imidazolyl, with one or more substituents indepently selected from hydroxy, methoxy, halogen and amino, or a salt or solvate thereof.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5458593A | 1993-04-29 | 1993-04-29 | |
| US08/054,585 | 1993-04-29 | ||
| US8104293A | 1993-06-22 | 1993-06-22 | |
| US08/081,042 | 1993-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2161681A1 true CA2161681A1 (en) | 1994-11-10 |
Family
ID=26733234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002161681A Abandoned CA2161681A1 (en) | 1993-04-29 | 1994-04-28 | Water soluble derivatives of camptothecin and their use as antitumor agents |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0696285A1 (en) |
| JP (1) | JPH08509740A (en) |
| AP (1) | AP9400638A0 (en) |
| AU (1) | AU6777194A (en) |
| CA (1) | CA2161681A1 (en) |
| IL (1) | IL109470A0 (en) |
| IS (1) | IS4152A (en) |
| MY (1) | MY141374A (en) |
| PE (1) | PE52894A1 (en) |
| WO (1) | WO1994025466A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6504029B1 (en) * | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| US5663177A (en) * | 1995-05-31 | 1997-09-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| SG104284A1 (en) | 1996-10-30 | 2004-06-21 | Tanabe Seiyaku Co | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof |
| US6559309B2 (en) | 1996-11-01 | 2003-05-06 | Osi Pharmaceuticals, Inc. | Preparation of a camptothecin derivative by intramolecular cyclisation |
| US6046209A (en) * | 1997-05-27 | 2000-04-04 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0418099T3 (en) * | 1989-09-15 | 2002-04-02 | Res Triangle Inst | Process for Preparation of 10,11-Methylenedioxy-20 (RS) Camptothecin and 10,11-Methylenedioxy-20 (S) Camptothecin Analogs |
| DE69209969T2 (en) * | 1991-10-29 | 1996-09-12 | Glaxo Wellcome Inc | Water soluble camptothecin derivatives |
| CA2087898A1 (en) * | 1992-01-24 | 1993-07-25 | Hiroshi Akimoto | Condensed heterocyclic compounds, their production and use |
-
1994
- 1994-04-25 IS IS4152A patent/IS4152A/en unknown
- 1994-04-27 MY MYPI94001039A patent/MY141374A/en unknown
- 1994-04-27 PE PE1994241061A patent/PE52894A1/en not_active Application Discontinuation
- 1994-04-28 AU AU67771/94A patent/AU6777194A/en not_active Abandoned
- 1994-04-28 WO PCT/US1994/004681 patent/WO1994025466A1/en not_active Application Discontinuation
- 1994-04-28 CA CA002161681A patent/CA2161681A1/en not_active Abandoned
- 1994-04-28 AP APAP/P/1994/000638A patent/AP9400638A0/en unknown
- 1994-04-28 JP JP6524540A patent/JPH08509740A/en active Pending
- 1994-04-28 EP EP94915931A patent/EP0696285A1/en not_active Withdrawn
- 1994-04-28 IL IL10947094A patent/IL109470A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE52894A1 (en) | 1995-01-06 |
| IL109470A0 (en) | 1994-07-31 |
| IS4152A (en) | 1994-10-30 |
| JPH08509740A (en) | 1996-10-15 |
| EP0696285A1 (en) | 1996-02-14 |
| AU6777194A (en) | 1994-11-21 |
| MY141374A (en) | 2010-04-16 |
| AP9400638A0 (en) | 1995-10-28 |
| WO1994025466A1 (en) | 1994-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0540099B1 (en) | Water soluble camptothecin derivatives | |
| US5342947A (en) | Preparation of water soluble camptothecin derivatives | |
| AU652728B2 (en) | Camptothecin analogs as potent inhibitors of human colorectal cancer | |
| US6100273A (en) | Water soluble camptothecin derivatives | |
| US4894456A (en) | Synthesis of camptothecin and analogs thereof | |
| RU2380368C2 (en) | Deazapurines and use thereof | |
| US5122526A (en) | Camptothecin and analogs thereof and pharmaceutical compositions and method using them | |
| WO1990003169A1 (en) | Synthesis of camptothecin and analogs thereof | |
| EP0496634A1 (en) | Substituted phenyl-1,3-dioxoloquinoline derivatives and their use as antitumor agents | |
| US5364858A (en) | Camptothecin analogs as potent inhibitors of topoisomerase I | |
| EP0251361A1 (en) | New di- and tetrahydroisoquinoline derivatives | |
| CA2161681A1 (en) | Water soluble derivatives of camptothecin and their use as antitumor agents | |
| AU738322B2 (en) | New acronycine compounds, a process for their preparation and pharmaceutical compositions containing them | |
| NZ520377A (en) | New benzo[b]pyrano[3,2-h]acridin-7-one compounds, a process for their preparation and pharmaceutical compositions containing them | |
| GB2280674A (en) | Pyrido[3,4-b]-pyridine antitumor compounds | |
| PL173684B1 (en) | Derivatives of camptotecine, method of obtaining sames, pharmaceutical preparation containing them and method of inhibiting the topoisomeraze i enzyme | |
| SI9300183A (en) | water soluble camptothecin derivates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |